Genomic advances have enhanced our understanding of schizophrenia, bipolar disorder and major depressive disorder, revealing genetic architectures and risk mechanisms through large-scale genome-wide association studies and sequencing, which could address limitations in current diagnostic frameworks and treatment strategies in the future.
- Michael J. Owen
- Nicholas J. Bray
- Michael C. O’Donovan